U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Monday.
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) rose sharply during Monday's session after the company released ORIGIN Phase 3 trial data.
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36.
Vera Therapeutics shares jumped 56.6% to $29.67 on Monday.
Here are some other big stocks recording gains in today’s session.
Now Read This:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
